AZ, Bristol-Myers hopeful on dapagliflozin second try, but FDA staff remains wary

AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) are heading back to the FDA with the once-spurned dapagliflozin, claiming they've addressed the diabetes drug's cancer risks, but agency staff remains wary of the treatment's dangers. Report